Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Double-Blind Placebo-Controlled Trial Of The Safety, Toleration and Efficacy Of Lasofoxifene 0.25 Md/D and Raloxifene 60mg/D For The Prevention Of Bone Loss In Postmenopausal Women.

Next Previous
X
Search
Trial Profile

Double-Blind Placebo-Controlled Trial Of The Safety, Toleration and Efficacy Of Lasofoxifene 0.25 Md/D and Raloxifene 60mg/D For The Prevention Of Bone Loss In Postmenopausal Women.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 12 May 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lasofoxifene (Primary) ; Raloxifene
  • Indications Bone resorption; Postmenopausal osteoporosis
  • Focus Registrational; Therapeutic Use
  • Acronyms CORAL
  • Sponsors Pfizer

    • Most Recent Events

    • 17 Apr 2016 Results comparing efficacy of Raloxifene and Lasofoxifene presented at the 2016 World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases.
    • 06 Apr 2016 According to a Sermonix Pharmaceuticals media release, the company will present data from this study at the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Disease (WCO-IOF-ESCEO)
    • 09 Oct 2015 Results will be presented at the upcoming American Society for Bone and Mineral Research Annual Meeting (ASBMR), as per Sermonix media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top